Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2016 by Roswell Park Cancer Institute
Information provided by (Responsible Party):
Roswell Park Cancer Institute Identifier:
First received: December 14, 2009
Last updated: September 9, 2016
Last verified: September 2016
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: July 2017
  Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)